EARly Prevention of aTHeroma Progression

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 111 participants.

Also called NCT02105623

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 111 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02105623
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02105623. Randomized; no masking; primary purpose treatment. Start 2014-06 (actual); primary completion 2018-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EARly Prevention of aTHeroma Progression
Acronym
EARTH
Condition
Coronary Arteriosclerosis
Intervention (Behavioral)
Standard Therapy
Intervention (Drug)
Rosuvastatin
Lead sponsor
CHEOL WHAN LEE, M.D., Ph.D (class: other)
Collaborator
CardioVascular Research Foundation, Korea (class: other)

Record details

Record id
cardio:ct-nct02105623
Content hash
0219cff666eacfa452d812d4645766ce030c3e53f55e1cdc7898e1b7592bea7e